Navigation Links
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
Date:7/15/2009

nts observed in these patients were generally consistent with expectations for patients with advanced HIV infection and with the multiple drugs being administered.(8)

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's clinical development plans and the potential for vicriviroc. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchang
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
2. Schering-Plough Announces Results of the Early ACS Trial
3. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
4. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
5. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
8. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
9. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
10. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... OrthoWorx, the newly formed industry, community and ... sector in Kosciusko County, is working to connect the ... Chicago and Cleveland via high-speed rail. ,, In a ... Orthopedics Capital of the World -- An overview, ... BioCrossroads, the statewide initiative to grow Indiana,s ...
(Date:12/15/2009)... PITTSBURGH, Dec. 15 Ever wonder what something ... samples! ASPEX, makers of the Personal Scanning Electron Microscope ... encouraging people to send in samples to be scanned ... PSEM has a scan range of 100nm to 5mm ... the smallest samples into focus. In addition, ASPEX will ...
(Date:12/15/2009)... --A Harvard medical expert internationally recognized as a ... Tour,s decision last month to suspend Doug Barron ... as having the medical condition hypogonadism ... "unreasonable, unfair and discriminatory." ,, Hypogonadism ... levels, often referred to informally as Low ...
Breaking Medicine Technology:OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 2OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 3ASPEX Kicks Off Free 'Send Us Your Sample' Microscopy Campaign 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4The Leapfrog Group Releases Its 2009 Top Hospitals List 62654 1The Leapfrog Group Releases Its 2009 Top Hospitals List 62654 2The Leapfrog Group Releases Its 2009 Top Hospitals List 62654 3NHLBI Grant Awarded to Wake Forest Pitt to Improve Banked Blood 6770 1NHLBI Grant Awarded to Wake Forest Pitt to Improve Banked Blood 6770 2NHLBI Grant Awarded to Wake Forest Pitt to Improve Banked Blood 6770 3FDA Approves Lillys Zyprexa for Two Adolescent Indications 6768 1FDA Approves Lillys Zyprexa for Two Adolescent Indications 6768 2FDA Approves Lillys Zyprexa for Two Adolescent Indications 6768 3FDA Approves Lillys Zyprexa for Two Adolescent Indications 6768 4FDA Approves Lillys Zyprexa for Two Adolescent Indications 6768 5FDA Approves Lillys Zyprexa for Two Adolescent Indications 6768 6FDA Approves Lillys Zyprexa for Two Adolescent Indications 6768 7
... Company reaffirms its innovation leadership and long-term commitment to ... KENILWORTH, N.J., Nov. 24 Schering-Plough Corporation (NYSE: ... boceprevir, its lead investigational oral hepatitis C protease inhibitor ... boceprevir has the potential to be a first-in-class and ...
... Nov. 24 GeneThera, Inc.,(Pink Sheets: GTHR.PK), announces it will ... through its Wheat Ridge, Colo. laboratory. , ... Johne,s disease testing service as,soon as January of 2009. ... to be offering our real time PCR test for Johne,s ...
Other Medicine Technology:Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4
(Date:12/16/2009)... Ltd. is proud to announce being presented with the Weatherhead 100 ... the fastest growing companies in Northeast Ohio and is a testament ... , ... (PRWEB) December 16, 2009 -- ... the Weatherhead 100 Upstart Award on December 3, 2009. The ...
(Date:12/16/2009)... Ennis, P.A. will continue to offer free nationwide confidential legal ... Paxil side effects such as: Birth Defects, Attempted Suicide, Suicide ... call toll free at 1-800-856-6405 or go to the firm’s ... case evaluation form. , ... (PRWEB) ...
(Date:12/15/2009)... developed a new electrophoretic method for detecting MIRCERA ... The technique, using SARCOSYL-PAGE, has specifically enhanced sensitivity ... characteristics of SDS-PAGE for detecting other EPOs. ... from the World Anti-Doping Agency (WADA), appear in ... Analysis published by Wiley-Blackwell. , MIRCERA (methoxy ...
(Date:12/15/2009)... SNKTY), a Life Sciences company engaged in the research, development and commercialization of technologies that ... that the Company had proposed at the Annual General Meeting of Shareholders held on December ... Votes ... Non-, Matter ... For Against ...
(Date:12/15/2009)... the Lupus Foundation of America and the Saint Thomas, ... -- Julian Lennon, son of the legendary John Lennon, ... single, "LUCY," to raise funds for research on the ... percent of the proceeds from downloading "LUCY" at iTunes ... (LFA), and the Saint Thomas, Lupus Trust in Great ...
Breaking Medicine News(10 mins):Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 3Health News:Researchers discover novel method for detecting MIRCERA 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2
... for double mastectomy , , WEDNESDAY, Dec. 3 (HealthDay News) -- ... her breast removed when she was just 14, the second ... the third lump, she was 25 and had watched her ... and her mother endure both chemotherapy and radiation after being ...
... 3 Micromet, Inc.,(Nasdaq: MITI ), a ... cancer, inflammation and autoimmune diseases,will host a webcast and ... Eastern Time (8:00 p.m. Central European Time) to discuss ... of Hematology,(ASH) meeting. , ...
... its expertise in serving 60 million Americans, OptumHealth developed myOptumHealth.com ... free access to clinically reviewed, easy-to-understand and actionable content, tools ... ... MN (PRWeb) December 3, 2008 -- OptumHealth Inc. , ...
... Holden today announced that Mr Richard Bowden had officially taken over ... ... VIC (PRWEB) December 3, 2008 -- Bupa Asia Pacific Managing Director ... over as Managing Director of the company., , ,Bupa Australia is ...
... AGA Medical Corporation announced,today that it received European CE ... The ACP provides an innovative, minimally,invasive solution for closing ... use will be for the non-surgical occlusion of the ... "The ACP is an important addition to the interventional ...
... MRI (fMRI) have determined that the circuitry in the ... dysfunctional in patients suffering from stress-related psychiatric disorders. Results ... annual meeting of the Radiological Society of North America ... other stress-related disorders, traumatic memories are a source of ...
Other Medicine News:Health News:More High-Risk Women Preempt Breast Cancer 2Health News:More High-Risk Women Preempt Breast Cancer 3Health News:Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting 2Health News:Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting 3Health News:OptumHealth Launches myOptumHealth.com, Consumer-Focused Health and Wellness Information Web Site 2Health News:OptumHealth Launches myOptumHealth.com, Consumer-Focused Health and Wellness Information Web Site 3Health News:New Managing Director for Bupa Australia 2Health News:AGA Medical Receives European CE Mark Approval for AMPLATZER(R) Cardiac Plug 2Health News:Stress-related disorders affect brain’s processing of memory 2
... CycloPhotocoagulation (ECP) is a surgical approach to ... visualized laser application. The ciliary body (which ... surgeon, from the anterior or posterior segment, ... target tissues are easily and accurately identified ...
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... Centuries of German Craftsmanship have ... in the world. Ocutek® now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek® ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Medicine Products: